First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance
Abstract
Pan-FGFR inhibitors face toxicity and acquired resistance in FGFR3-altered cancers. This Viewpoint highlights the first covalent FGFR3-selective inhibitor, a promising agent addressing isoform selectivity and clinically acquired resistance in targeted therapy.
Fields of Study & Subjects
Fibroblast Growth Factor Research
Lung Cancer Treatments and Mutations
Heterocyclic Compound Synthesis and Bioactivity
Publication details
- Journal / source
- Journal of Medicinal Chemistry
- Volume
- 69
- Issue
- 5
- Pages
- 5166–5168
- Publication date
- 27 February 2026
- Language
- EN